

Remarks:

This is in response to the Official Action of February 12, 2004 for the above-captioned application. A Petition for revival of an unintentionally abandoned application under 37 c.f.r. §1.137(b) is enclosed.

Applicants elect with traverse the invention of Group I, corresponding to Claims 1-9, 16-25 and 32-38. The Official Action's requirement for the election of a species is traversed since it is respectfully submitted that all claims may be examined without undue burden on the Examiner. Applicants respectfully point out that, according to MPEP 803, for restriction to be proper, "[t]here must be a serious burden on the examiner." MPEP 803 further states that "serious burden" may be shown by "separate classification, or separate status in the art, or a different field of search...." It is respectfully submitted that the Official Action has not made the required showing of undue burden.


Applicants note the Official Action's statement that the withdrawn claims that depend from or include all limitations of an allowable product claims will be rejoined under MPEP 821.04. Applicants further reserve the right to pursue any non-elected claims in a separate application or applications.

In view of the foregoing, examination and allowance of all pending claims in the application is respectfully requested.

Please charge any appropriate fee to cover this submission to Pfizer Deposit Account
No. 16-1445. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: January 7, 2005



Andrea E. Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer, Inc.
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-1898